Jefferies analyst Thomas Wei reiterated a Buy rating and raised his price target Biogen (NASDAQ: BIIB) from $318 to $358.
This article: 127 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE